...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current drug research reviews. >Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer
【24h】

Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer

机译：低剂量纳曲酮:潜在的好处影响其使用的癌症患者

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Naltrexone (NTX) is an opioid antagonist that inhibits cell proliferation in vivo when administered in low doses. Naltrexone in low doses can reduce tumor growth by interfering with cell signalling as well as by modifying the immune system. It acts as an Opioid Growth Factor receptor (OGFr) antagonist and the OGF-OGFr axis is an inhibitory biological pathway present in human cancer cells and tissues, being a target for the treatment with naltrexone low-dose (LDN). Clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors. LDN shows promising results for people with primary cancer of the bladder, breast, liver, lung, lymph nodes, colon and rectum. This short review provides further evidence to support the role of LDN as an anticancer agent.
机译：环丙甲羟二羟吗啡酮(NTX)是一种阿片拮抗物抑制细胞增殖时体内在低剂量服用。剂量可以降低肿瘤的生长通过干扰细胞信号传导以及通过修改免疫系统。(OGFr)受体拮抗剂和OGF-OGFr轴是一个抑制生物通路人类癌症细胞和组织,作为一个目标治疗和环丙甲羟二羟吗啡酮低剂量(LDN)。提出了一个独特的临床试验机制(s)允许LDN影响肿瘤。显示了患者主要有前景的结果癌症的膀胱、乳腺癌、肝癌、肺癌、淋巴节点、结肠和直肠。提供了进一步的证据支持的角色LDN作为抗癌剂。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号